NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Adult Solid Neoplasm

Interventions: Drug: Erlotinib Hydrochloride
Drug: Irinotecan Hydrochloride

First Posted Date: 2003-01-27

Last Posted Date: 2025-02-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00045201

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer

Phase 3

Terminated

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel
Radiation: radiation therapy
Drug: thalidomide

First Posted Date: 2003-01-27

Last Posted Date: 2014-06-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 589

Registration Number: NCT00004859

Locations: 🇺🇸
Sletten Regional Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States
🇺🇸
Doctors Hospital at Ohio Health, Columbus, Ohio, United States
🇺🇸
Swedish Covenant Hospital, Chicago, Illinois, United States

and more 230 locations

Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas

Phase 1

Completed

Conditions: Untreated Childhood Gliosarcoma
Untreated Childhood Anaplastic Oligodendroglioma
Untreated Childhood Anaplastic Astrocytoma
Untreated Childhood Brain Stem Glioma
Untreated Childhood Giant Cell Glioblastoma
Untreated Childhood Glioblastoma
Untreated Childhood Gliomatosis Cerebri
Untreated Childhood Oligodendroglioma

Interventions: Drug: gefitinib
Radiation: radiation therapy
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2014-05-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 69

Registration Number: NCT00042991

Locations: 🇺🇸
Pediatric Brain Tumor Consortium, Memphis, Tennessee, United States

Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer

Phase 2

Completed

Conditions: Stage II Pancreatic Cancer
Adenocarcinoma of the Pancreas
Stage III Pancreatic Cancer

Interventions: Drug: gemcitabine hydrochloride
Drug: tipifarnib
Drug: paclitaxel
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2020-10-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 154

Registration Number: NCT00026104

Locations: 🇺🇸
Radiation Therapy Oncology Group, Philadelphia, Pennsylvania, United States

Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis

Phase 2

Completed

Conditions: Colorectal Cancer
Familial Adenomatous Polyposis

Interventions: Drug: Celecoxib
Other: Placebo
Drug: eflornithine
Other: Laboratory biomarker analysis
Other: Questionnaire administration

First Posted Date: 2003-01-27

Last Posted Date: 2020-09-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 205

Registration Number: NCT00033371

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Recurrent Ovarian Epithelial Cancer
Primary Peritoneal Cavity Cancer
Stage IV Ovarian Epithelial Cancer

Interventions: Biological: bevacizumab
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2019-07-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 64

Registration Number: NCT00022659

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3000

Registration Number: NCT00031928

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸
Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States

and more 6 locations

Combination Chemotherapy in Treating Patients Who Have Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-30

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00020488

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

Fluorescent Light Bronchoscopy Plus White Light Bronchoscopy for Early Detection of Lung Cancer

Not Applicable

Completed

Conditions: Lung Cancer
Head and Neck Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-29

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00019201

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

Gene Therapy and Biological Therapy in Treating Patients With Ovarian Epithelial Cancer

Phase 1

Completed

Conditions: Ovarian Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-29

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00019136

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy